索拉非尼联合射频消融与单纯索拉非尼治疗侵犯门静脉的肝细胞癌的比较：一项西方随机对照试验
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
作者信息
Giorgio Antonio, Merola Maria Gabriella, Montesarchio Luca, Merola Francesca, Santoro Bruno, Coppola Carmine, Gatti Pietro, Amendola Ferdinando, DI Sarno Antonella, Calvanese Andrea, Matteucci Paolo, Giorgio Valentina
机构信息
Interventional Ultrasound Unit, Tortorella Clinical Institute, Salerno, Italy
Interventional Ultrasound Unit, Athena Cinical Institute, Caserta, Italy.
出版信息
Anticancer Res. 2016 Nov;36(11):6179-6183. doi: 10.21873/anticanres.11211.
AIM
To compare in a randomized controlled trial (RCT) 3-year survival of cirrhotic patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) treated with sorafenib plus percutaneous radiofrequency ablation (RFA) of both intraparenchymal HCC and PVTT (combination Group) or sorafenib alone (sorafenib-alone Group).
PATIENTS AND METHODS
Ninety-nine consecutive Child A cirrhotics were randomized to receive RFA of both HCC and main portal vein tumor thrombus (MPVTT) plus sorafenib (n=49) or sorafenib alone (n=50).
RESULTS
One-, 2- and 3-year survival rates were 60%, 35% and 26%, respectively, in the combination group and 37% and 0 % at 1- and 2-year, respectively, in the sorafenib alone group. At multivariate analysis, the combination of RFA of both HCC and MPVTT was the only factor predicting survival.
CONCLUSION
Use of RFA of both HCC and MPVTT plus sorafenib significantly increases 3-year survival compared to sorafenib alone.
目的
在一项随机对照试验（RCT）中比较索拉非尼联合经皮射频消融（RFA）治疗肝实质内肝癌和门静脉癌栓（PVTT）的肝细胞癌（HCC）肝硬化患者（联合治疗组）与单独使用索拉非尼治疗（索拉非尼单药组）的3年生存率。
患者和方法
99例连续入选的Child A级肝硬化患者被随机分为两组，分别接受肝癌和主要门静脉癌栓（MPVTT）的RFA联合索拉非尼治疗（n = 49）或单独使用索拉非尼治疗（n = 50）。
结果
联合治疗组1年、2年和3年生存率分别为60%、35%和26%，索拉非尼单药组1年和2年生存率分别为37%和0%。多因素分析显示，肝癌和MPVTT的RFA联合治疗是预测生存的唯一因素。
结论
与单独使用索拉非尼相比，肝癌和MPVTT的RFA联合索拉非尼治疗可显著提高3年生存率。
Zotero 插件